NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | 0.03 | 0.09 | -0.06 |
| FCF Yield | -32.55% | -31.02% | -18.89% | -12.70% |
| EV / EBITDA | -0.42 | -1.26 | -4.07 | -5.40 |
| Quality | ||||
| ROIC | -19.94% | -18.13% | -20.82% | -21.12% |
| Gross Margin | -213.94% | 14.09% | 21.36% | 50.20% |
| Cash Conversion Ratio | 0.83 | 0.94 | 1.05 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -61.58% | -33.62% | -28.55% | -24.34% |
| Free Cash Flow Growth | 15.67% | 31.96% | 5.05% | -37.78% |
| Safety | ||||
| Net Debt / EBITDA | 2.02 | 1.64 | 1.26 | 1.26 |
| Interest Coverage | -11.65 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.75 | 0.75 |
| Cash Conversion Cycle | -486.47 | -844.20 | -303.80 | -898.23 |